OCUL Ocular Therapeutix Inc.

4.18
+0.1  (+2%)
Previous Close 4.08
Open 4.08
Price To Book 17.42
Market Cap 200,972,791
Shares 48,079,615
Volume 783,532
Short Ratio
Av. Daily Volume 503,215
Stock charts supplied by TradingView

NewsSee all news

  1. Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  2. Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

  3. Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  4. Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

    Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quarter of 2020 Topline

  5. Ocular Therapeutix Announces Strategic Update and Operational Restructuring

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval June 21, 2019.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial initiation announced September 24, 2019. Top-line data due 1H 2020.
DEXTENZA
Allergic conjunctivitis
Phase 3 data May 20, 2019 did not meet primary endpoint.
OTX-TP
Glaucoma and ocular hypertension
FDA approval announced December 3, 2018.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease
Phase 1 initial data released April and May 2019.
OTX-TIC
Glaucoma and ocular hypertension
Phase 1 dosing of first patient announced February 20, 2019.
OTX-TKI
Wet Age-related Macular Degeneration (AMD)

Latest News

  1. Ocular Therapeutix™ to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  2. Lyra Therapeutics Appoints Bradford Smith to its Board of Directors

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and

  3. Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  4. Ocular Therapeutix™ Reports Third Quarter 2019 Financial Results and Business Update

    Over 7,000 Patients Treated Since Launch at more than 350 Surgical Sites Expanded the DEXTENZA® Field Team by 50% Implemented Restructuring Plan That Extends Cash Runway Through the Fourth Quarter of 2020 Topline

  5. Ocular Therapeutix Announces Strategic Update and Operational Restructuring

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced an operational

  6. Ocular Therapeutix™ To Report Third Quarter 2019 Financial Results

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  7. Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it

  8. Ocular Therapeutix Announces Permanent J-Code for DEXTENZA® (dexamethasone ophthalmic insert) Effective October 1, 2019

    Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the

  9. Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that

  10. Ocular Therapeutix™ to Present at the 2019 Wells Fargo Healthcare Conference

    Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that